Tocopherols (CID 86472) - BioAssay Data Summary for Compound
.
BioActivity Outcomes:
Active(2)
 
 
Inactive(402)
 
 
Unspecified(26)
 
 
Top Targets:
7TM GPCR Srx(15)
 
 
7TM GPCR Srsx(6)
 
 
alkPPc(4)
 
 
Peptidase C48(4)
 
 
BRLZ(3)
 
 
BioAssay Types:
Screening(272)
 
 
 
Confirmatory(122)
 
 
 
Literature(30)
 
 
 
 
BioActivity Types:
Potency(110)
 
 
 
IC50(12)
 
 
 
SAR
Target summary
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 409    Data Row: 430   Total Pages: 9   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103282296]
 Prodrug conversion in 3D restructured human skin model assessed as conversion of compound to dl-alpha-tocopherol at 2% after 4 hrs by HPLC analysis [AID631221, Type: Literature]
View
2
[SID57264399]
 HTS to identify compounds that promote myeloid differentiation with MLPCN compound set [AID624256, Type: screening]
View
3
[SID103282296]
IC50 500Compound was tested for antiproliferative activity against human breast cancer cell line MCF-7 in MTT assay [AID103204, Type: Literature]
View
4
[SID103282296]
 In vivo activity against triglycerides (TG) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 100 mg/Kg dose [AID111641, Type: Literature]
View
5
[SID103282296]
 Inhibition of soybean arachidonate 15-lipoxygenase by oxygen electrode method [AID336951, Type: other]
View
6
[SID103282296]
 Antioxidant activity assessed as inhibition of Fe2+-induced lipid peroxidation after 15 to 60 mins by TBARS assay relative to control [AID416726, Type: Literature]
View
7
[SID103282296]
 In vivo activity against triglycerides (TG) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 300 mg/Kg dose [AID111644, Type: Literature]
View
8
[SID103282296]
 In vitro inhibitory activity against rat microsomal lipid peroxidation (m-LPO) [AID179764, Type: Literature]
View
9
[SID103282296]
 Antioxidant activity in rat liver microsomes assessed as inhibition of lipid peroxide formation after 30 mins [AID336950, Type: other]
View
10
[SID103282296]
 Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans [AID588211, Type: Literature]
View
11
[SID103282296]
 Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents [AID588212, Type: Literature]
View
12
[SID103282296]
 Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents [AID588213, Type: Literature]
View
13
[SID103282296]
 In vivo activity against hypocholesterol (CHOL) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 100 mg/Kg dose [AID111628, Type: Literature]
View
14
[SID103282296]
 In vivo activity against hypocholesterol (CHOL) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 300 mg/Kg dose [AID111631, Type: Literature]
View
15
[SID103282296]
 In vivo activity against serum lipid peroxidation level (s-LPO) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 10 mg/Kg dose [AID111632, Type: Literature]
View
16
[SID103282296]
 In vivo activity against serum lipid peroxidation level (s-LPO) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 100 mg/Kg dose [AID111633, Type: Literature]
View
17
[SID103282296]
 In vivo activity against serum lipid peroxidation level (s-LPO) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 300 mg/Kg dose [AID111636, Type: Literature]
View
18
[SID103282296]
 In vivo activity against serum lipid peroxidation level (s-LPO) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 50 mg/Kg dose [AID111638, Type: Literature]
View
19
[SID103282296]
 In vivo activity against triglycerides (TG) by Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 50 mg/Kg dose [AID111639, Type: Literature]
View
20
[SID103282296]
 In vivo activity against triglycerides (TG) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 10 mg/Kg dose [AID111640, Type: Literature]
View
21
[SID103282296]
 In vivo activity against hypocholesterol (CHOL) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 10 mg/Kg dose [AID111627, Type: Literature]
View
22
[SID103282296]
 In vivo activity against hypocholesterol (CHOL) by Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 50 mg/Kg dose [AID111626, Type: Literature]
View
23
[SID103282296]
 Protection against H2O2-induced cell damage in NHEK assessed as inhibition of PGE2 production at 2 uM pretreated for 24 hrs before H2O2 challenge measured after 24 hrs by enzymatic immunoassay [AID631235, Type: Literature]
View
24
[SID103282296]
 Protection against t-BHP-induced cell damage in NHEK assessed as inhibition of PGE2 production at 2 uM pretreated for 24 hrs before t-BHP challenge measured after 24 hrs by enzymatic immunoassay [AID631240, Type: Literature]
View
25
[SID103282296]
 Protection against IL1-beta-induced cell damage in NHEK assessed as inhibition of PGE2 production at 2 uM pretreated for 24 hrs before IL1-beta challenge measured after 24 hrs by enzymatic immunoassay [AID631276, Type: Literature]
View
26
[SID103282296]
 Protection against IL1-beta-induced cell damage in NHEK assessed as inhibition of PGE2 production at 0.5 uM pretreated for 24 hrs before IL1-beta challenge measured after 24 hrs by enzymatic immunoassay [AID631277, Type: Literature]
View
27
[SID103282296]
 Protection against IL1-beta-induced cell damage in NHEK assessed as inhibition of PGE2 production at 0.1 uM pretreated for 24 hrs before IL1-beta challenge measured after 24 hrs by enzymatic immunoassay [AID631278, Type: Literature]
View
28
[SID57264399]
Potency qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate [AID624178, Type: confirmatory]acid sphingomyelinase [Homo sapiens] [gi:179095]
View
29
[SID57264399]
Potency qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate [AID624178, Type: confirmatory]acid sphingomyelinase [Homo sapiens] [gi:179095]
View
30
[SID57264399]
Potency 0.8913A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. [AID624297, Type: confirmatory]GMNN gene product [Homo sapiens] [gi:7705682]
View
31
[SID57264399]
Potency 7.3078qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation [AID540253, Type: confirmatory]snurportin-1 [Homo sapiens] [gi:5031833]
View
32
[SID29218011]
Potency 28.1838qHTS Assay for Inhibitors of GCN5L2 [AID504327, Type: confirmatory]histone acetyltransferase KAT2A [Homo sapiens] [gi:153791535]
View
33
[SID29218011]
Potency 28.1838qHTS Assay for Inhibitors of GCN5L2 [AID504327, Type: confirmatory]histone acetyltransferase KAT2A [Homo sapiens] [gi:153791535]
View
34
[SID57264399]
Potency qHTS Assay for Inhibitors of GCN5L2 [AID504327, Type: confirmatory]histone acetyltransferase KAT2A [Homo sapiens] [gi:153791535]
View
35
[SID57264399]
Potency qHTS Assay for Inhibitors of GCN5L2 [AID504327, Type: confirmatory]histone acetyltransferase KAT2A [Homo sapiens] [gi:153791535]
View
36
[SID57264399]
 HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS [AID485317, Type: screening]FAD-linked sulfhydryl oxidase ALR [Homo sapiens] [gi:54112432]
View
37
[SID29218011]
Potency qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate [AID2107, Type: confirmatory]alpha-galactosidase [Homo sapiens] [gi:757912]
View
38
[SID29218011]
Potency qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate [AID2107, Type: confirmatory]alpha-galactosidase [Homo sapiens] [gi:757912]
View
39
[SID57264399]
Potency qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) [AID624417, Type: confirmatory]glp-1 receptor [Homo sapiens] [gi:1724069]
View
40
[SID57264399]
Potency qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) [AID624417, Type: confirmatory]glp-1 receptor [Homo sapiens] [gi:1724069]
View
41
[SID124893249]
Potency qHTS of GLP-1 Receptor Agonists [AID624172, Type: confirmatory]glp-1 receptor [Homo sapiens] [gi:1724069]
View
42
[SID124893249]
Potency qHTS of GLP-1 Receptor Agonists [AID624172, Type: confirmatory]glp-1 receptor [Homo sapiens] [gi:1724069]
View
43
[SID57264399]
Potency qHTS of GLP-1 Receptor Agonists [AID624172, Type: confirmatory]glp-1 receptor [Homo sapiens] [gi:1724069]
View
44
[SID57264399]
Potency qHTS of GLP-1 Receptor Agonists [AID624172, Type: confirmatory]glp-1 receptor [Homo sapiens] [gi:1724069]
View
45
[SID57264399]
Potency qHTS for Inhibitors of Glutaminase (GLS) [AID624170, Type: confirmatory]GLS protein [Homo sapiens] [gi:71051501]
View
46
[SID124893249]
Potency qHTS for Inhibitors of Glutaminase (GLS) [AID624170, Type: confirmatory]GLS protein [Homo sapiens] [gi:71051501]
View
47
[SID57264399]
Potency qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS [AID624288, Type: confirmatory]Guanine nucleotide-binding protein G(s) subunit alpha isoforms short [gi:52000961]
View
48
[SID57264399]
 Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha [AID2650, Type: screening]GSK3A gene product [Homo sapiens] [gi:49574532]
View
49
[SID57264399]
 Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha [AID2650, Type: screening]GSK3A gene product [Homo sapiens] [gi:49574532]
View
50
[SID57264399]
 FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1) [AID485270, Type: screening]orexin receptor type 1 [Homo sapiens] [gi:222080095]
View